Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of Kaposi sarcoma
3.2.1.2 Increased healthcare expenditure
3.2.1.3 Growing number of research and development activities
3.2.1.4 Increasing advancement in treatment options
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Limited awareness among healthcare providers and patients
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Types, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Epidemic kaposi sarcoma
5.3 Classic kaposi sarcoma
5.4 Endemic kaposi sarcoma
5.5 Iatrogenic kaposi sarcoma
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Radiation therapy
6.3 Chemotherapy
6.4 Immunotherapy
6.5 Highly active antiretroviral therapy (HAART)
6.6 Other treatments
Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Hospitals
7.3 Specialty centers
7.4 Homecare
7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca Plc
9.2 Bausch Health Companies Inc.
9.3 Baxter International, Inc.
9.4 Bristol Myers Squibb
9.5 Eisai Inc.
9.6 Merck & Co.
9.7 Navidea Biopharmaceuticals
9.8 Pfizer, Inc.
9.9 Regeneron Pharmaceuticals
9.10 Sun Pharmaceuticals Industries Ltd.
